Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07291180 · ClinicalTrials.gov registry record · NA
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
A NA study of Colorectal Adenocarcinoma and Appendiceal Cancer, sponsored by Yale University.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07291180 is a NA study of Colorectal Adenocarcinoma and Appendiceal Cancer that is actively recruiting participants, run by Yale University. The registered enrollment target is 20 participants, below the 318-participant average among 19 other Colorectal Adenocarcinoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07291180, a NA study of Colorectal Adenocarcinoma and Appendiceal Cancer, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade appendiceal adenocarcinomas (HGAA) and colorectal cancer (CRC).
Conditions Studied
Interventions
- DEVICE Mass-based response testing (MRT)
Study Locations (1)
Connecticut
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07291180
The ClinicalTrials.gov registry entry for NCT07291180 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 318-participant average among 19 other Colorectal Adenocarcinoma trials with a reported enrollment target (94% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Colorectal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Mass-based response testing (MRT) is the first listed.
NCT07291180 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT07291180 about?
NCT07291180 is a clinical study titled "A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis". This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade appendiceal adenocarcinomas (HGAA) and colorectal cancer (CRC).
What is the current status of trial NCT07291180?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2026-03. Estimated completion is 2027-12.
What conditions does trial NCT07291180 study?
This clinical trial studies the following conditions: Colorectal Adenocarcinoma, Appendiceal Cancer, Peritoneal Metastases.
What interventions are being tested in trial NCT07291180?
The interventions under investigation include: Mass-based response testing (MRT) (DEVICE).
Who is sponsoring clinical trial NCT07291180?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07291180 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RECRUITING · Phase 1
-
Early Onset Colorectal Cancer Detection
RECRUITING
-
Stage II/III Colorectal Cancer Recurrence
RECRUITING
-
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.